APM-176
CFTR-Related Disorders (Chronic Rhinosinusitis, Pancreatitis, IBS-C, Liver Cirrhosis, Bronchiectasis)
Phase 2Active
Key Facts
Indication
CFTR-Related Disorders (Chronic Rhinosinusitis, Pancreatitis, IBS-C, Liver Cirrhosis, Bronchiectasis)
Phase
Phase 2
Status
Active
Company
About Ariel Precision Medicine
Ariel Precision Medicine is a private, pre-revenue biotech applying artificial intelligence to precision medicine for complex diseases. Its core asset is the ADVANCE platform, which analyzes deep genetic, clinical, and environmental data to identify novel disease subtypes and therapeutic targets. The company's lead program, APM-176, is a Phase 2-ready oral small molecule targeting multiple CFTR-related chronic conditions, positioning Ariel to address a significant unmet need in a validated biological pathway. The company's strategy hinges on using AI to de-risk drug development and personalize patient care.
View full company profile